Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Vivus Inc (VVUS)

Vivus Inc (VVUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Vivus Inc 900 E. HAMILTON AVENUE SUITE 550 CAMPBELL CA 95008 USA

P: 650-934-5200

Description:

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in Phase 3 development with avanafil, its PDE5 inhibitor drug candidate, and in Phase 2 development of Luramist(TM), its drug candidate for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS.

Key Statistics

Overview:

Market Capitalization, $K 8,335
Shares Outstanding, K 17,867
Annual Sales, $ 69,760 K
Annual Net Income, $ -31,500 K
Last Quarter Sales, $ 19,630 K
Last Quarter Net Income, $ -5,210 K
60-Month Beta -0.84
% of Insider Shareholders 12.00%
% of Institutional Shareholders 7.32%
Float, K 15,723
% Float 88.00%

Growth:

1-Year Return -86.24%
3-Year Return -96.24%
5-Year Return -97.35%
5-Year Revenue Growth -38.90%
5-Year Earnings Growth 61.56%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 08/04/20
Earnings Per Share ttm -2.70
EPS Growth vs. Prev Qtr 19.67%
EPS Growth vs. Prev Year 34.67%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00
Most Recent Split 1-10 on 09/11/18

VVUS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -1.05
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -12.18%
Profit Margin % -45.15
Net Margin % N/A
Debt/Equity N/A
Price/Sales 0.13
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -6.94
Interest Coverage -0.52
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar